Publication|Videos|October 3, 2024
FSP Partnership: A Foundation for Innovation and Patient-Guided Development
Author(s)PAREXEL
Liz Rogers, VP and Head of Global Site and Study Operations at Pfizer, discusses Pfizer's partnership with Parexel and transition to a functional service provider (FSP) model.
- Transitioning to an FSP model, strategically allocating resources, and leveraging partnerships introduced a more streamlined and efficient model, enhancing resource efficiency and flexibility. The approach has enabled the sponsor (Pfizer) to tap into specialized expertise while maintaining control and oversight of clinical operations.
- Growing core capabilities in site and study management further enhanced site performance and oversight of quality and compliance. Further strengthening relationships with sites is key to the strategy alongside supporting novel recruitment models, shifting to remote monitoring, and focusing on fewer, higher-performing clinical sites.
Related Content
Trending on Applied Clinical Trials Online
1
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Breaking the Efficacy Ceiling in IBD and Beyond
5